This trial is looking for a better way to treat hemophilia A, a genetic disorder where the body does not create enough of a protein called clotting factor 8 (FVIII) present in the blood.
1 Primary · 6 Secondary · Reporting Duration: Up to 24 months
Experimental Treatment
33 Total Participants · 1 Treatment Group
Primary Treatment: Damoctocog alfa pegol (Jivi, BAY94-9027) · No Placebo Group · Phase 3
Age 7 - 11 · Male Participants · 4 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: